If Wegovy 2.4mg Isn't Working, Here Is What the Evidence Tells You

What the STEP 1 data actually shows about non-responders at 2.4mg

The STEP 1 trial, published in the New England Journal of Medicine, randomised nearly 2,000 adults with obesity to semaglutide 2.4mg or placebo alongside lifestyle support. The headline (roughly 15% average weight loss at 68 weeks) is accurate, but averages smooth over real variation. A meaningful proportion of participants lost less than 5%, and a smaller number lost almost nothing despite staying on the dose correctly. Researchers have since looked at predictors of response: those who lost at least 5% of body weight in the first 16 weeks were far more likely to reach clinically significant loss by the end of the trial. Slow early response is therefore a signal worth discussing with your prescriber, not something to quietly push through for another six months without review. NICE's guidance on semaglutide for weight management reflects this, it advises considering whether to continue if less than 5% weight loss has occurred after six months at the maintenance dose.

None of that means 2.4mg has failed permanently. It means the dose needs clinical evaluation. If you want to understand more about how Wegovy's dosing schedule is structured from the beginning, our Wegovy doses guide covers the full titration path.

Biological reasons why 2.4mg Wegovy may not be working for you

Semaglutide is a GLP-1 receptor agonist. It slows gastric emptying, reduces appetite signals in the brain, and increases the feeling of fullness after eating. The degree to which each of those effects translates into reduced calorie intake varies between people, driven by differences in gut-hormone receptor sensitivity, baseline metabolic rate, and how the body adapts over time. Some people experience what researchers call energy-intake compensation: appetite returns more than expected between doses, particularly in the day or two before each weekly injection. A consistent pattern of increased hunger towards the end of each week is worth mentioning to your prescriber.

Lifestyle factors interact with the drug too. Semaglutide is licensed alongside a reduced-calorie diet and increased physical activity, those components are not optional footnotes. If sleep quality is poor, stress is high, or ultra-processed foods are making up a large share of intake, the biological environment the medicine works in is less favourable. That is not a character judgement; it is pharmacology. Your prescriber can help you work out which factors are at play.

It is also worth checking the practical basics. Are you storing your pens correctly, refrigerated at 2–8°C until use? Pens left outside this range for too long can lose potency. The exact room-temperature window is set out in the Patient Information Leaflet that arrives with your treatment. And if you have recently missed a weekly dose, that gap can disrupt the steady-state concentration the medicine relies on.

The 7.2mg option: what the newer evidence means for people stuck at 2.4mg

If you have been on 2.4mg Wegovy for at least six months and weight loss has plateaued or never reached 5%, there is now a clinically meaningful next step available in the UK. The MHRA approved a higher 7.2mg maintenance dose for Wegovy in January 2026, and then approved a dedicated single-dose 7.2mg pen on 14 April 2026. Trials of this higher dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap between semaglutide and tirzepatide, and substantially above what STEP 1 showed at 2.4mg. This option is licensed for adults with a BMI of 30 or above and is subject to clinical assessment before any prescriber would move you to it.

The titration still starts at 0.25mg and moves up through the established schedule, the 7.2mg dose is the ceiling, not the starting point, and your prescriber decides whether it is appropriate for your specific circumstances. If you are wondering how Wegovy fits into the broader picture of weight-loss treatment options, our weight-loss treatment overview sets out what is currently licensed and available. For a full picture of costs involved in ongoing treatment, the Wegovy cost page covers what private prescriptions typically include.

When to contact your prescriber, and when to get urgent help

Lack of weight loss is a reason for a clinical conversation, not an emergency. But some symptoms during Wegovy treatment do warrant prompt attention. Severe, persistent stomach pain (especially if it radiates towards your back, with or without vomiting) can be a sign of pancreatitis, which the MHRA highlighted in a January 2026 Drug Safety Update as an infrequent but serious potential side effect of GLP-1 medicines. Go to A&E or call 999 for severe abdominal pain. For more moderate concerns (nausea that is not settling, appetite returning strongly, or simply feeling that something is not quite right) contact your prescriber. At nume, our prescribers and aftercare team are available seven days a week for exactly this kind of question.

If you started your Wegovy journey at a lower dose and felt little effect there too, you might find it useful to read what others at an earlier stage experience on pages covering the 1mg dose not working, what happens when 0.5mg produces little response, or 1.7mg not producing results, patterns across the titration can help your prescriber identify whether the issue is dose-specific or broader. And if you are questioning whether Wegovy is right for you at all, our clinical team profile at Mostafa Damghani's page gives a sense of the clinical oversight behind every decision. A free consultation is the right starting point, check your eligibility and a GPhC-registered prescriber will review your situation the same day.